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Abstract. It was recently shown (Sampson et al., Elife 9, 2020) that an amyloidogenic protein, CsgA, present in E. coli
biofilms in the gut can trigger Parkinson’s disease in mice. This study emphasizes the possible role of the gut microbiome
in modulation (and even initiation) of human neurodegenerative disorders, such as Parkinson’s disease. As the CsgA pro-
tein was found to accelerate alpha-synuclein (the key amyloidogenic protein in Parkinson’s disease) amyloid formation in
vitro, this result suggests that also other amyloidogenic proteins from gut bacteria, and even from the diet (such as stable
allergenic proteins), may be able to affect human protein conformations and thereby modulate amyloid-related diseases. In
this review, we summarize what has been reported in terms of in vitro cross-reactivity studies between alpha-synuclein and
other amyloidogenic human and non-human proteins. It becomes clear from the limited data that exist that there is a fine
line between acceleration and inhibition, but that cross-reactivity is widespread, and it is more common for other proteins
(among the studied cases) to accelerate alpha-synuclein amyloid formation than to block it. It is of high importance to expand
investigations of cross-reactivity between amyloidogenic proteins to both reveal underlying mechanisms and links between
human diseases, as well as to develop new treatments that may be based on an altered gut microbiome.
Keywords: Parkinson’s disease, alpha-synuclein, amyloid formation, cross-reactivity, functional amyloids, food allergens,
neurodegeneration, microbiome
INTRODUCTION
The name amyloid was first used in medical lit-
erature by Rudolf Virchow in 1854 who used it to
wrongly identify deposits in the nervous system as
starch (amylum in Latin). For a while, the scientific
community debated whether amyloid deposits con-
tained fat or carbohydrates until it was shown in 1859
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that they are, in fact, protein deposits. In 1907, Alois
Alzheimer reported a patient with dementia who
had plaques (now, known to be extracellular amy-
loids) but it took until 1960s before the cross--sheet
structure of amyloids and experimental methods to
detect and isolate amyloids were developed. In sub-
sequent years many amyloid-related human diseases
were discovered. Today, we know that the aberrant
self-assembly of proteins into amyloid fibers in dif-
ferent organs and tissues is a unifying molecular
event in up to 50 human diseases, including sev-
eral neurodegenerative disorders (e.g., Alzheimer’s,
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Parkinson’s, Huntington’s and amyotrophic lateral
sclerosis (ALS) diseases) as well as systemic (e.g.,
amyloid light chain (AL) and serum amyloid A (AA)
amyloidosis) and local (e.g., type-2 diabetes) diseases
[1]. Although proteins with different primary and
secondary structures all adopt similar cross--sheet
amyloid structures in the various disorders, mecha-
nisms and triggers behind the self-assembly remain
unknown and may vary from protein to protein.
Parkinson’s disease
Parkinson’s disease (PD) [2, 3], is the sec-
ond most common neurodegenerative disorder after
Alzheimer’s disease and the most common move-
ment disorder. PD is characterized by widespread
deterioration of subcortical structures of the brain,
especially dopaminergic neurons in the substantia
nigra [4]. These changes are coupled to bradykine-
sia, rigidity and tremor, resulting in difficulties in
walking and abnormal gait in patients [4]. Assem-
bly of the protein alpha-synuclein (aS) into amyloid
fibrils is linked to the molecular pathology of PD,
with aS amyloids being the major content of the
pathological neuronal inclusions, Lewy bodies, found
post-mortem in the brain of PD patients [5–7] and
considered PD hallmarks. The number of patients
with PD in the world is increasing but we have no
cure: there are only symptomatic drugs in the form of
L-DOPA (and derivatives thereof), which is a precur-
sor of dopamine, and electrodes inserted into patients’
brains; both approaches have only temporary effects.
In accord with the key role of aS in PD, duplica-
tions, triplications and point-mutations in the aS gene,
enhancing concentration and aggregation propensity,
are linked to familial PD cases [8]. It is thought
that aS assembly to amyloid fibers via intermedi-
ate oligomers results in toxic gain-of-functions, that
are coupled to mitochondrial dysfunction, oxidative
stress, protein degradation failure, and eventually cell
death [9]. Soluble aS oligomers have been proposed
to be most toxic [10, 11], but work with pre-formed
S fibrils have demonstrated that the amyloid fib-
rils themselves are toxic and can be transmitted from
cell to cell and are also able to cross the blood-brain
barrier [12–14].
Functional amyloids
Despite the initial association of amyloids with
proteins involved in neurodegenerative disorders, in
the last two decades, proteins from all kingdoms of
life have been reported to form functional amyloids
[15]. For example, biofilms are structures used by
bacteria to adhere to surfaces which contain amyloids
such as curli proteins [16, 17]. Human functional
amyloids include proteins in the signaling pathway
leading to necrosis (Rip1-Rip3 co-assemblies) [18]
and in melanosome ultra-structures (fragments of the
pre-melanosome protein, PMEL) [19]. Recently, it
was revealed that food allergens may adopt amy-
loid states that confer protection against the harsh
conditions during gastrointestinal transit and allow
for uptake in the blood. This was reported for aller-
genic food proteins such as whey and casein proteins
in milk, ovalbumin and lysozyme in egg, and -
parvalbumin in fish [20–23]. In fact, test tube studies
have shown that most proteins can form amyloids at
certain (often extreme, structure-perturbing) solution
conditions [24].
ALPHA-SYNUCLEIN PROPERTIES
The aS gene was cloned in 1993 [25] and the con-
nection of the protein with PD was made in 1997 [8].
aS is a 140-residue polypeptide that can be divided
in three parts: N-terminal, NAC (Non-Amyloid-
 Component) and C-terminal regions (Fig. 1A).
Whereas the N-terminus (residues 1–60) is amphi-
pathic with many basic residues, the C-terminus
(residues 95–140) is acidic with many negatively
charged residues. The NAC region (residues 61–94) is
hydrophobic and contains several amino-acid repeats
which constitute the core of the amyloid structures
formed upon aS aggregation. Most PD cases are spo-
radic, but there are disease-causing mutations, all
found in the N-terminal part (A30P, E46K, H50Q,
G51D, A53T/E/V), that promote early-onset PD [9].
aS is acetylated at the N-terminus in vivo [26] and
posttranslational modifications such as phosphoryla-
tion, ubiquitination, and C-terminal truncations are
found in aS aggregate deposits [9].
Biophysical characterization and biological
functions
The aS monomer is intrinsically disordered in solu-
tion with some charge-charge interactions between
N- and C-termini that shield the NAC region [27].
aS displays high affinity for negatively charged lipid
vesicles: the N-terminal 100 residues adopt a heli-
cal structure when bound to vesicles. Chemical (e.g.,
lipid headgroup chemistry) and physical (e.g., cur-
vature, rafts) properties of lipid vesicles appear to
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Fig. 1. A) Scheme of aS’s polypeptide with N-terminal (blue), NAC (yellow) and C-terminal (red) parts indicated as well as known disease-
causing mutations (stars). B) Typical aggregation curve of aS as probed by ThT fluorescence (lag, growth and plateau phases indicated).
C) AFM image of aS amyloid fibers. D) High-resolution structures (2N0A, 6A6B, 6FLT, 6CU7, and 6CU8; Table 1) of aS amyloid fiber
cores.
sensitively modulate the binding mode of aS and,
at some conditions, formation of amyloids are trig-
gered by vesicles [28]. aS appears to have many
functions and interaction partners in human cells. A
key activity of aS in brain cells is proposed to be
modulation of synaptic-vesicle trafficking, fusion and
release [29–31]. In accord, aS is often localized at
presynaptic nerve terminals associated with synaptic
vesicles [32–34] but it has also been found associ-
ated with mitochondrial membranes [35] and in the
nucleus [36]. Outside the brain, aS is expressed in,
for example, red blood cells, islets of the pancreas
and enteroendocrine cells of the gut epithelium. The
latter cells form a direct neural circuit from the gut
to the brain [37]. This may be of high importance
for spreading of PD, as it was recently speculated
that the gut microbiome can initiate and modulate
PD [38]. aS is annotated as a copper-binding protein
in uniprot.org and copper (Cu) ions can bind readily
in vitro; in cells, it appears that Cu can be delivered
to aS via the copper chaperone Atox1 [39]. aS inter-
action with Cu may be of functional relevance as Cu
ions like neurotransmitters are involved in synapse
signaling and Cu ions are loaded in the synaptic vesi-
cles that aS is believed to traffic in the presynapse [40,
41]. It remains unknown if initiation of PD involves
aberrant aS functional interactions or whether there
are external (not related to normal function) triggers
of aS aggregation.
Purpose of this review
Since amyloid fibers have similar structures, there
may be generic aspects of aggregation processes that
allow for interactions between different amyloido-
genic proteins. Cells are crowded with biomolecules
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[42]. In fact, up to 40% of the available volume
in a cell is occupied by other macromolecules.
The crowded environment results in many effects
including amplified opportunities for non-specific
inter-protein interactions [43–50]. In this review, we
summarize what is known about how other amyloido-
genic proteins affect aS amyloid formation kinetics.
We focus on in vitro studies of cross-reactivity, as
truly the use of purified proteins is the only way
to probe effects of protein-protein interactions on a
molecular level. Nonetheless, to be biologically rele-
vant, biophysical studies should always be followed
up by in vivo studies and we will mention cell/animal
work when appropriate. For more comprehensive
descriptions of co-aggregation and co-localization
of amyloidogenic proteins in cells (not necessarily
involving aS), see [51, 52]. After describing aS amy-
loid formation and how to detect assembly in vitro,
we discuss data concerning the effects of first human
amyloidogenic proteins and then non-human amy-
loidogenic proteins on aS amyloid formation, before
ending with a concluding section.
ALPHA-SYNUCLEIN AMYLOID
FORMATION IN VITRO
Aggregation of aS into amyloid fibers can be
probed in vitro using monomeric aS protein (fresh
from a gel filtration column) that is placed at 37◦ C,
often with some shaking and glass-beads to speed up
the reaction. At these conditions, the aS amyloid for-
mation reaction, normally monitored in real time by
Thioflavin T (ThT) fluorescence, shows a sigmoidal
curve (Fig. 1B) in which there is first a lag time (no
change in ThT fluorescence), followed by a growth
phase (drastic increase in ThT fluorescence) and then
a plateau is reached (no further change in ThT fluores-
cence). In the very beginning of amyloid formation
(assuming a purely monomeric starting solution) the
formation of the first small aggregates takes place via
primary nucleation, which is commonly very slow.
This is followed by polymerization/elongation, often
involving secondary processes, such as secondary
nucleation on amyloid fiber surfaces and fiber frag-
mentation (creating new nuclei). Most often, both
primary and secondary pathways play roles in the
overall reaction scheme [53]. With careful kinetic
data at a range of protein concentrations and con-
ditions, aspects of the underlying molecular mecha-
nisms can be deduced from global fitting procedures
[54]. It is reported that for aS, primary processes
dominate at physiological pH, whereas at lower pH,
secondary processes become more important [55].
Experimental methods
Whereas ThT probe the appearance of amyloid
fibers, other experimental methods can be used for
complementary assessment. Far-UV circular dichro-
ism (CD) provides information about aS secondary
structure and can be used to follow the transition
from random coil (start, monomer) to -sheet (end,
amyloid fiber) structures. To confirm that the ThT
data truly reports on amyloid fiber formation, and
to macroscopically characterize the formed amy-
loids, scientists turn to electron microscopy (EM) and
atomic force microscopy (AFM) analyses (Fig. 1C).
Although the fibers need to be attached to surfaces
before analyses, and the methods are not quantita-
tive, many properties of the amyloids can be revealed,
such as cross-section size, length, straight vs. curly,
presence of branching, etc. To bypass aS’s slow pri-
mary nucleation, and sometimes used to get more
reproducible kinetic data, one can add aS seeds (i.e.,
preformed aS amyloid fibers; most often sonicated
samples) to the aS monomer solution. Also the addi-
tion of lipid vesicles (at certain lipid to protein ratios)
and metal ions can catalyze aS aggregation [28, 56].
Cross-reactivity with other amyloidogenic proteins
is another (but less explored) way that aS amyloid
formation kinetics can be perturbed.
Cross-reactivity and amyloid strains
With cross-reactivity we mean how another amy-
loidogenic protein (in monomer or amyloid form)
may affect aS amyloid formation via direct protein-
protein interactions. Another amyloidogenic protein,
when added as a monomer, may co-aggregate with aS
to speed up amyloid formation or it may interact with
aS monomers to block further aS amyloid formation.
In similarity, for pre-formed amyloid fibers of other
amyloidogenic proteins, they may either seed aS
monomers to aggregate faster (heterologous seeding)
or they may inhibit aS monomers to form amyloids.
In all the cases, this requires interactions between dif-
ferent amyloidogenic proteins and such are proposed
to be governed by ‘conformational selection and pop-
ulation shift’, meaning that one or both proteins need
to be flexible and able to adjust their conformations to
compatible binding states [57]. Using high-resolution
methods (solid-state NMR and cryo-EM), aS amyloid
fibers have been found to adopt different morpholo-
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Table 1
High-resolution aS amyloid structures reported in PDB; from the
first one (by solid-state NMR) published in 2016 and subsequent
ones (by cryo-EM) until February 2020, along with comments in
some cases. The first five structures are shown in Fig. 1D
PDB file Year Reference Comments
2N0A 2016 [87] Solid state NMR
6A6B 2018 [88]
6FLT 2018 [89]
6CU7 2018 [90] Rod
6CU8 2018 [90] Twister
6SSX 2019 [91] Polymorph 2A
6SST 2019 [91] Polymorph 2B
6OSL 2019 [92] 1–122, acetylated
6OSM 2019 [92] 1–103, acetylated
6OSJ 2019 [92] 1–140, acetylated
6PEO 2019 [93] H50Q narrow fibril
6PES 2019 [93] H50Q wide fibril
6UFR 2020 [94] E46K
6LRQ 2020 [95] A53T
6XYQ 2020 not yet published Multiple system atrophy,
type II-2
6XYO 2020 not yet published Multiple system atrophy,
type I
6XYP 2020 not yet published Multiple system atrophy,
type II-1
gies (sometimes called strains) depending on the
aggregation conditions. In fact, the amyloid folds
adopted by different amyloidogenic proteins, includ-
ing aS, are unexpectedly diverse and complex [58].
In Table 1, we summarize high-resolution structures
of aS amyloids reported in the Protein Data Bank
(deposited up to February 2020), and the first five
structures are illustrated in Fig. 1D. It is not clear
how amyloid-core structural differences relate to aS
amyloid toxicity and PD propagation, but one may
speculate that, in addition to solution conditions,
interactions with other amyloidgenic proteins may
induce different final amyloid structures. However,
all reported high-resolution structures have been gen-
erated by aS polypeptides alone, expect the three
last entries (still unpublished studies) in Table 1 that
are sarkosyl-insoluble fractions from the putamen of




In type-2 diabetes, the hormone amylin (islet
amyloid polypeptide, IAPP), made from the longer
unprocessed peptide pro-IAPP, forms amyloids in
pancreatic -cells. This leads to -cell dysfunction,
cell death and development of diabetes. Since it was
found that upon deletion of the gene Ide (coding for
the insulin degrading enzyme, IDE) in mice, the ani-
mals developed diabetes and the levels of both IAPP
and aS in the pancreas increased [59, 60], the idea of
cross-reactivity between IAPP and aS arose. In addi-
tion to pancreatic cells, IAPP is also found in the brain
and there has been reports suggesting that type-2 dia-
betes patients are predisposed to get PD but underly-
ing molecular mechanisms are not known [61]. When
purified IAPP and pro-IAPP peptides were tested in
aS amyloid formation reactions in vitro, it was found
that whereas IAPP pre-formed amyloid seeds speed
up aS amyloid formation, pro-IAPP amyloid seeds
instead reduce aS amyloid formation (Table 2). When
monomers of IAPP was mixed with monomers of aS,
aggregation was accelerated (faster than either pro-
tein alone) and immunogold staining of the resulting
amyloid fibers revealed that the amyloids contained
both peptides [62]. In contrast, pro-IAPP monomers
mixed with aS monomers resulted in aggregation that
was slower than that for aS alone. Taken together, the
cross-reactivity between both monomers and amyloid
fibers of IAPP in aS aggregation hints to a possible
explanation for the predisposition of type-2 diabetes
patients towards PD.
Amyloid-β
Alzheimer’s disease is characterized by accu-
mulation of extracellular amyloid- plaque and
intracellular amyloids (so-called tangles) of another
protein, tau. Interestingly, more than half of
Alzheimer’s disease cases exhibit Lewy body pathol-
ogy, in addition to amyloid- plaques and tau tangles,
and patients with dementia with Lewy bodies often
also exhibit amyloid- plaques. Thus, interactions
between amyloid- and aS may be involved in pro-
moting pathology. In vitro experiments showed that
amyloid fiber seeds of amyloid- speed up amyloid
formation of aS (but not as much as amyloid seeds
of aS itself) [63]. Also cross-linked oligomers of
amyloid- were tested as seeds and were found to
promote aS aggregation, but these were not as potent
as the amyloid- fiber seeds [63]. In another study
[64], it was found that when monomeric amyloid-
was added to monomeric aS in a sub-stoichiometric
molar ratio, coaggregation was observed and the
kinetics became much faster (Table 2). Immuno-
gold staining of the resulting amyloids demonstrated
that amyloid- was incorporated in the aS amy-
loids. The amyloid fibers formed in the presence
of monomeric amyloid- appeared thicker than aS-
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Table 2
Effects of human and non-human amyloidogenic proteins (in monomer and amyloid forms) on aS amyloid formation kinetics reaction in
vitro
Amyloidogenic protein Effect on aS amyloid formation reaction References
In monomer form In amyloid form
Human:
IAPP Acceleration + coaggregation Acceleration [62]
Pro-IAPP Inhibition Inhibition [62]
S100A9 Acceleration No effect [69]
Tau (K19, tau23) Acceleration + coaggregation Acceleration [68]
Amyloid- (1–40, 1–42, 3–42) Acceleration + coaggregation Acceleration [63, 64]
Non-human:
Parvalbumin fish No effect Inhibition [96]
CsgA bacteria Acceleration Acceleration [78]
FapC bacteria Inhibition (when using less amyloidogenic variant) No effect [80]
Insulin bovine – Acceleration [83]
Lysozyme hen – Acceleration [83]
GroES bacteria – Acceleration [83]
only fibers [64]. In these experiments, no aggregation
kinetics of amyloid- alone was shown as a control
and, thus, it is unclear if the added small amount
of monomeric amyloid- first formed homogeneous
amyloid- fibers that then seeded aS amyloid forma-
tion (and got incorporated in the aS amyloids), or if
there was true coaggregation of protein monomers to
mixed-protein amyloids.
Tau
Tau is an intrinsically disordered microtubule-
binding protein that is abundant in the central nervous
system. As mentioned above, intracellular deposits of
tau amyloids (tangles) is a hallmark of Alzheimer’s
disease along with extracellular amyloid- plaques.
However, in the tau amyloid deposits, aS can some-
times be found, and tau amyloids have been detected
in some PD patients. Since tau and aS appeared to
cross-react in neuronal cell experiments [65], in vitro
assessment of direct protein-protein interactions, and
consequences, were performed [66]. Tau alone does
not aggregate unless a trigger is added, such as hep-
arin. However, when monomeric tau (in the absence
of heparin) was added to aS, at a condition at which aS
alone did not aggregate (i.e., no shaking, low concen-
tration), it was found that aS amyloid formation was
stimulated (Table 2). The resulting amyloids (likely
containing both proteins) were morphologically dif-
ferent from amyloids of the individual proteins; the
amyloid fibers from the co-incubated sample showed
distinct twists and were thicker [67]. Also tau pre-
formed amyloid fibers (unclear how these were made;
there was no mentioning of heparin) added to aS
monomers in vitro accelerated aS amyloid formation
[68]. Tau monomers were found to interact with the
C-terminus of aS monomers, and it was proposed that
electrostatic attraction between the positive central
part of tau and aS’s negatively-charged C-terminus
would ‘open up’ the aS monomer conformation,
exposing the NAC domain [67]. In accord, tau did
not affect aggregation of an aS variant in which the
C-terminus had been removed [68].
S100A9
Neuroinflammation, which is linked to PD and
other neurodegenerative disorders, is associated
with increased levels of pro-inflammatory factors
in the brain. One such pro-inflammatory protein
is S100A9 that belongs to the large family of
calcium-binding S100 proteins that are involved in
many inflammatory, cancer and neurodegenerative
conditions [69], and are proposed to have intrinsic
amyloid-forming capacity [70]. S100A9 is reported
to be highly amyloidogenic: it was found in plaque
from Alzheimer’s disease patients and it could
modulate amyloid- aggregation in vitro [71]. Since
S100A9 was also found to co-localize with aS in
Lewy bodies, the possibility of cross-reactivity
with aS was investigated in vitro [69]. It was first
shown that S100A9 monomers interacted with the
C-terminus of aS monomers. When mixed in an
equimolar ratio as monomers, the two proteins
co-aggregated in a reaction that was faster than those
of the individual proteins. The resulting aggregates
also appeared larger than amyloids formed from
any of the proteins by themselves (Table 2). Also,
preformed amyloid fibers of S100A9 (not sonicated;
but prepared with agitation and glass bead so short)
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could speed up aS amyloid formation, but the effect
was less dramatic than upon addition of S100A9
monomers. As S100A9 becomes abundant in the
brain during neuroinflammation, it was suggested to
act as a common denominator in many inflammation-
dependent amyloid diseases. Interestingly, oligomers
formed by S100A9-aS mixtures were less toxic than




CsgA was the first functional amyloid described
(by Chapman et al. in 2002 [72]) and is the main
component of extracellular curli fibers in biofilms
made by E. coli and other bacteria. E. coli pos-
sesses at least six proteins, encoded by the csgBA and
csgDEFG operons, that are dedicated to curli biogen-
esis. CsgA is the major curli fiber subunit protein; it
contains five imperfect repeating units (19–23 amino
acids long), each predicted to form a -strand-loop--
strand motif, proposed to constitute the amyloid core
of CsgA amyloid fibers [73]. The biofilm helps the
organism to adhere to surfaces, for example in the gas-
trointestinal tract where humans host a vast number of
microorganisms [74, 75]. Several studies have indi-
cated roles for the gastrointestinal tract and the enteric
nervous system (ENS) in PD. In fact, Lewy bodies are
often observed in neurons of the ENS in early stages
of PD and, the appendix has been suggested to play
(conflicting) roles in PD initiation [76]. ENS neu-
rons can be found in the wall of the gastrointestinal
tract and connect directly with enteroendocrine cells
which, in turn, communicate with the gut content.
Thus, the microbiome may interact with the brain
through the ENS. An initial study showed that when
rats were fed curli-producing E. coli, there was an
increase in aS aggregation as compared to animals
that had been fed curli-deficient E. coli [77]. A sub-
sequent study showed that the bacterial composition
of the microbiome, or products produced by these
bacteria, in aS-expressing mice can lead to increase
in aS brain deposits, neuroinflammation and motor
deficits [38]. From these studies, it was proposed that
alterations in the human microbiome represent a risk
factor for PD. To search for a possible molecular
mechanism, in vitro experiments with purified CsgA
and aS were recently reported [78]. Mixing of CsgA
and aS, both in monomer forms, with CsgA at a sub-
stoichiometric molar ratio of 1 : 25 CsgA:aS (and at
such a low concentration that CsgA did not aggregate
on its own) was found to accelerate aS amyloid for-
mation in vitro (Table 2). Since the amount of added
CsgA was sub-stoichiometric, a catalytic mechanism
involving transient interactions were proposed and
this conclusion agreed with lack of stable interac-
tions found in surface plasmon resonance binding
experiments [78]. Also, CsgA preformed amyloids
accelerated aS amyloid formation in vitro (unpub-
lished results), and the same has been reported for
CsgA fibers added to amyloid- monomers [79]. The
cross-reactivity between CsgA and aS was shown
to depend on CsgA’s amyloid-forming ability as aS-
expressing mice mono-colonized with E. coli bacteria
which produced an amyloid-deficient CsgA protein
(or mice injected with a non-amyloidogenic mutant of
CsgA) did not show as much aS aggregation and had
less motor impairments as compared to mice in cor-
responding experiments with wild-type CsgA [78].
FapC
FapC is a functional amyloid protein produced
mainly by members of the Pseudomonas genus. Like
CsgA, FapC amyloids provide structural stability to
bacterial biofilms, but has fewer amyloid-promoting
repeating units in the polypeptide than CsgA (three
versus five). To elucidate the mechanism of FapC
amyloid formation and the role of the amyloidogenic
repeating units, various variants of FapC were char-
acterized in vitro. It was found that upon removal of
all repeats, the protein still aggregated, albeit slower,
and this delay in amyloid formation allowed for
disulfide-bond formation between cysteine residues
in monomers, which further delayed the aggrega-
tion [80]. Since Pseudomonas is relatively abundant
in the gut [81], the authors decided to test for
cross-reactivity between FapC and aS in vitro. Sur-
prisingly, the slower-aggregating variant of FapC was
found to delay aS aggregation, whereas wild-type
FapC showed slightly accelerating or no effect on
aS amyloid formation kinetics (Table 2). The inter-
action between the FapC mutant and aS resulted in
small (dead-end) oligomers containing both proteins
in vitro. In contrast, pre-formed amyloids of either
wild-type or mutant FapC did not affect aS amyloid
formation kinetics [80].
Parvalbumin
The most common allergen in fish, the highly
abundant protein -parvalbumin (PV), forms amy-
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Fig. 2. Illustration of the cross-reactivity results reported in Table
2, indicating the amyloidogenic proteins (as monomers or amy-
loids) that accelerate aS amyloid formation (bottom box) and the
ones that reduce/block aS aggregation (top box).
loids that escape gastrointestinal degradation and
instead transits to the blood [20, 22, 82]. PV is a
small, calcium-binding protein with a helical struc-
ture that can transform to amyloids upon calcium
removal. Since fish is considered beneficial against
several age-related diseases including dementia and
Alzheimer’s disease, we speculated that protein com-
ponents in the fish, e.g., PV known to be taken up in
human blood [20], could provide benefits perhaps via
cross-reactivity with human amyloidogenic proteins
resulting in aggregation inhibition. In vitro, PV starts
to form amyloids as soon as calcium is removed with
EDTA. Mixtures of PV and aS monomers resulted in
aggregation reactions that where identical to PV-only
reactions. This implied that PV formed amyloids,
and this process blocked aS from amyloid formation
but did not affect PV’s intrinsic aggregation kinetics.
At these conditions, PV aggregated faster than aS
alone and subsequent experiments with pre-formed
PV amyloids, showed that it is PV amyloids that
inhibit aS aggregation (Table 2). It was proposed
that PV amyloids, perhaps via their protruding neg-
atively charged calcium-binding loops, scavenged
aS monomers to the surface. In accord, immuno-
gold staining experiments showed PV amyloids to be
covered with aS but upon calcium addition, aS was
released and started to aggregate. This study also pro-
vided some hints about the aggregation mechanism
of PV itself. As binding of aS to the PV amyloid sur-
face had no effect on PV aggregation kinetics, this
suggests that only primary (no secondary, including
secondary nucleation and fragmentation) processes
are involved in PV amyloid formation. In addition,
inhibition of amyloid formation via scavenging of
monomers to a pre-formed amyloid (of a different
protein) is a new inhibition mechanism not reported
before. It remains unclear if PV meets aS in humans
after eating fish, although one can speculate this to
be possible in the blood as well as in gut enteroen-
docrine cells. In confocal microscopy experiments,
fluorescently labeled PV amyloids are found to enter
enteroendocrine cells (unpublished results).
Others
The possibility that amyloid fibers generated from
unrelated proteins affect aS amyloid fiber formation
kinetics has been addressed in one study [83]. Here
amyloid fibers of the E. coli chaperonin GroES, hen
lysozyme, and bovine insulin were added to aS aggre-
gation reactions. Notably, all three amyloids could
accelerate aS amyloid formation dramatically in vitro
(Table 2). Immunogold staining revealed that the
added non-aS amyloid seeds were incorporated in
the aS amyloids, which appeared able to grow bi-
directionally from the initial seed amyloid [83].
CONCLUDING REMARKS
Neurodegenerative disorder cases are increasing
in the world, mainly because the population is get-
ting older. This is expected to become a huge burden
for healthcare systems in the future as we have
no cures for neither PD nor other neurodegenera-
tive diseases. In this review, we have focused on
aS and PD, and summarized cross-reactivity data
(acceleration or inhibition) between aS and other
amyloidogenic proteins (in monomer or amyloid
states), see Table 2 and Fig. 2. Human amyloido-
genic proteins such as amyloid-, tau and S100A9
can often be found together with aS in amyloid
deposits in PD patients. This suggests a link between
these amyloidogenic proteins on a molecular level.
In accord, in vitro experiments show that amyloid-,
tau, S100A9, IAPP and pro-IAPP all can modulate
aS amyloid formation kinetics in either or both of
monomer and amyloid states. There are many more
putative cross-reactivity reactions between aS and
human amyloidogenic proteins that await to be mech-
anistically assessed in vitro. For example, expression
of a mutant SOD1 (amyloidogenic protein in ALS)
in cells promoted cellular aS aggregation [84] and
inoculation of infectious prions into aS-expressing
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transgenic mice promoted extensive aS aggregate
deposits and exacerbated aS pathology [85]. These
studies hint to possible cross-reactivity on the molec-
ular level such that, in both cases, interaction with
the other protein (as monomer or amyloid) would
accelerate aS aggregation.
Today, it is evident that the human microbiome,
and even some food proteins, form amyloids [21].
In addition to Escherichia and Pseudomonas already
mentioned above, Streptoccocus, Staphylococcus,
Salmonella, Mycobacteria, Klebsiella, Citrobacter
and Bacillus species are found in the gut and make
extracellular amyloids. However, little is known
about the abundance of different bacterial amyloids
due to the large number of microbes (10-100 trillion in
each individual) and extensive variability of compo-
sition from person to person. Further studies of bac-
terial amyloids and amyloid-forming proteins in the
diet, that may escape the gastrointestinal tract (such
as PV, and perhaps other allergenic proteins), should
be pursued. We may find amyloidogenic proteins in
food that both accelerate and inhibit human amy-
loidogenic proteins and these may also cross-react
with amyloidogenic proteins in the gut microbiome.
Regardless of escaping the gastrointestinal tract or
not, food amyloids may modulate the gut microbiome
via cross-reactivity with bacterial amyloids. In this
context, it is important to note that scientists are look-
ing into ways to force food proteins towards amyloid
states as a method to improve food texture; this is done
because amyloids have favorable foaming, emulsify-
ing and gel properties [86]. Although most proteins
within our diet may be digested, even if in an amyloid
form, and levels of individual proteins may be very
low [21], one must be careful before using amyloids
in food and first assess possible toxicity in a case-by-
case basis. When duck or goose foie gras was injected
into transgenic mice, amyloids in the foie gras pro-
moted AA amyloidosis in the mice [23]. Although
this was an extreme experiment, the results emphasize
that amyloid-containing food products may hasten
aggregation of host proteins.
To understand the complex interplay between neu-
rodegeneration and diet as well as microbes, many
scientific disciplines must come together. Controlled
in vitro biophysical experiments with purified pro-
teins can act as the basis (providing intrinsic protein
properties) for subsequent interpretations of in vivo
observations, where admittedly the situation is more
complex. From the limited molecular in vitro data
that has been published on cross-reactivity between
aS and other amyloidogenic proteins, it emerges
that interactions often are observed and both inhibi-
tion and acceleration of aS amyloid formation can
result, with acceleration appearing more common
than inhibition (Table 2, Fig. 2). In fact, of the human
amyloidogenic proteins tested for cross-reactivity in
vitro, all accelerate aS amyloid formation except pro-
IAPP. One possibility is that the net effect in each
case depends on the intrinsic aggregation speed of
the interacting protein; in accord, pro-IAPP and the
FapC variant both aggregate slower than aS when
alone, and both inhibit aS amyloid formation. In
contrast, most of the proteins reported to acceler-
ate aS amyloid formation, aggregates faster than
aS individually. In addition, conformational plastic-
ity (allowing for compatibility despite differences in
sequence and structure among interacting proteins)
may play a key role [57]. To conclude, it is desired that
the scientific community collects more fundamental
knowledge of how other human and non-human amy-
loidogenic proteins modulate aS amyloid formation:
both to reveal underlying (causative) reasons for dis-
ease onset and as novel avenues towards the use of
gut bacteria (and perhaps diet) to counteract PD.
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